48,836
edits
Difference between revisions of "Prostate-specific antigen"
Jump to navigation
Jump to search
Prostate-specific antigen (view source)
Revision as of 16:39, 22 October 2014
, 16:39, 22 October 2014→Prostate specific antigen density
| Line 13: | Line 13: | ||
===Prostate specific antigen density=== | ===Prostate specific antigen density=== | ||
:Abbreviated ''PSAD''. | |||
*Normal is often | *Normal is often considered to be: <0.15 ng/ml. | ||
**Approximately 8% of individuals below the cut-point (0.15 ng/ml) have medium or high-grade cancer.<ref name=pmid12973074>{{Cite journal | last1 = Boulos | first1 = MT. | last2 = Rifkin | first2 = MD. | last3 = Ross | first3 = J. | title = Should prostate-specific antigen or prostate-specific antigen density be used as the determining factor when deciding which prostates should undergo biopsy during prostate ultrasound. | journal = Ultrasound Q | volume = 17 | issue = 3 | pages = 177-80 | month = Sep | year = 2001 | doi = | PMID = 12973074 }} | **Approximately 8% of individuals below the cut-point (0.15 ng/ml) have medium or high-grade cancer.<ref name=pmid12973074>{{Cite journal | last1 = Boulos | first1 = MT. | last2 = Rifkin | first2 = MD. | last3 = Ross | first3 = J. | title = Should prostate-specific antigen or prostate-specific antigen density be used as the determining factor when deciding which prostates should undergo biopsy during prostate ultrasound. | journal = Ultrasound Q | volume = 17 | issue = 3 | pages = 177-80 | month = Sep | year = 2001 | doi = | PMID = 12973074 }} | ||
</ref> | </ref> | ||